



ATC codes: C09DB04

Indication	Essential hypertension <span>ICD11 code: BA00.Z</span>
INN	Telmisartan + amlodipine
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 40 mg + 5 mg ; 80 mg + 5 mg ; 80 mg + 10 mg
EML status history	First added in 2019 (TRS 1021) Changed in 2021 (TRS 1035)
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations	Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and C08CA Dihydropyridine derivatives (for amlodipine)
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a> Read more <a href="#">about patents.</a>
Wikipedia	<a href="#">Telmisartan + amlodipine</a>
DrugBank	<a href="#">Telmisartan</a> , <a href="#">Amlodipine</a>

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroups, C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and C08CA Dihydropyridine derivatives (for amlodipine), be specified as therapeutic alternatives under the square box listing for telmisartan + amlodipine on the EML.

